News Image

BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation

Provided By PR Newswire

Last update: Jun 14, 2024

FROM ACF EQUITY RESEARCH HEALTHCARE TEAM

NASDAQ: BCLI

READ ACF EQUITY RESEARCH'S INITIATION NOTE HERE 

READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LOU GEHRIG'S HERE

Read more at prnewswire.com

BRAINSTORM CELL THERAPEUTICS

NASDAQ:BCLI (2/21/2025, 8:02:56 PM)

1.73

-0.07 (-3.89%)


Find more stocks in the Stock Screener

Follow ChartMill for more